Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc.

ZBHยทNYSE

$84.98

+1.5%
HealthcareMedical - Devices

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

At a Glance

Live Snapshot
Market Cap$16.44B
EPS3.5600
P/E Ratio23.87
Earnings Date08/06/2026
Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. Fair Value Envelope

ZBH ยท NYSE

Our analysis suggests that ZBH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.98, this represents a potential HIDDEN relative to our calculated worth for Zimmer Biomet Holdings, Inc..

Intrinsic Value
Current Price: $84.98

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$213.9B
+ Cash & Equivalents$591.9M
Firm Value$214.5B
- Debt$7.5B
Equity Value$207.0B
/ Shares Outstanding198,181,555B
DCF Value$1.0K
UNDERVALUED BY 1129%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$2.2B
$2.8B
$3.6B
$4.7B
$6.0B
$7.8B
$10.0B
$12.9B
$16.6B
$21.4B
Maintenance CapEx
-$57.9M
-$74.6M
-$96.1M
-$123.8M
-$159.6M
-$205.7M
-$265.1M
-$341.6M
-$440.2M
-$567.4M
Owner Earnings
$2.1B
$2.7B
$3.5B
$4.6B
$5.9B
$7.6B
$9.8B
$12.6B
$16.2B
$20.9B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$2.0B
$2.4B
$2.8B
$3.3B
$4.0B
$4.8B
$5.7B
$6.8B
$8.1B
$9.7B
Terminal Value represents 76.9% of Enterprise Value